We view it positively that existing shareholders choose to continue supporting the Company, while the issue is conducted in a shareholder-friendly manner.

OncoZenge is a Swedish research company developing BupiZenge™, a pain-relieving lozenge intended for the treatment of oral mucositis. The Company plans to conduct a European Phase 3 trial, which will form the basis for marketing authorisation of BupiZenge™ in Europe.

We note that the Company is in need of additional capital and assess that a directed share issue will likely be announced shortly. The focus remains on generating JDA projects and licensing agreements from the existing project portfolio, which we consider central to the investment case.

Mats also provides an outlook on the valuation expected from the sale of Sensec and the potential for a shareholder dividend. Finally, the discussion touches upon the order intake in Transfer Group’s subsidiaries and the outlook for Altum Security AB and Safe AB.

Net sales amounted to 1,862 thousand SEK, which corresponds to a growth of over 350% compared to Q2 2024. Compared to the first quarter of 2025, net sales increased by a whopping 44 %, which is considered strong.

Impala Nordic sees the decision as a positive imprint on the Company's project, given that a regulatory obstacle has been removed.

The Company is developing Ayla, the world's first dementia-care platform, aiming to reach operational break even by mid 2026.

Including the agreements with Eways and Arval, which are expected to contribute annual revenues in the million range.

At the same time, the Company has strengthened its sales organization by recruiting key competence. Both the agreement and the recruitment increase Prebona's sales opportunities through access to an extensive distribution network.

To offer a complete solution for electric vehicle charging to Arval's leasing customers in Sweden. The agreement is expected to significantly increase recurring revenue.

The fact that DUG continues to secure significant store listings strengthens the thesis of high growth potential in the coming years.

Lappland Guldprospektering is a Swedish company active in gold prospecting with a focus on developing and conducting gold mining on a larger scale in Sweden and the rest of the Nordic region.

Delayed launches and high inventory levels negatively affected net sales in the quarter.

She explains how the Ayla platform delivers Cognitive Stimulation Therapy to improve memory and attention, and discusses the UK healthcare system and efforts to integrate Brain+'s CST solution.

The report, as expected, contained no surprises. The focus remains on securing the final regulatory approvals for the investment agreement with Yangtian Pharma, in order to initiate the phase 3 study of BupiZenge™.

Net sales were negatively affected by changed accounting procedures, which means that growth is not visible compared to the comparison period. In reality, net sales are growing by just over 15% compared to Q1 2024, and we assess that the activities the Company has carried out set the stage for a strong 2025.

The main focus is on beverages, where the company's brand DUG offers an alternative to milk and other non-dairy-based beverages.

In our assessment, the report contains no surprises, and the focus is still on securing license agreements.

The company will receive SEK 224 million before issue costs through the rights issue, which are considered low as the issue was carried out without any guarantee commitments. In addition, the company has carried out a directed new issue to selected investors of SEK 41.6 million, which further strengthens the cash position.

The subscription price corresponds to a premium of approximately 11.1 percent compared to the closing price of SEK 9 on April 15, 2025.

The Company is currently conducting a rights issue of SEK 208 million to secure capital for the early readout of the Company's phase 3 study DIAGNODE-3 in March 2026.

They talk about their backgrounds, the path to profitability and growth – both organically and through acquisitions – and share their vision for the future.

Impala Nordic gives its view on the case, where majority-owned Eleven Stories is particularly interesting. The Company's guidance for 2025 and the view on the current valuation are also commented on.

Carbiotix now has a total of 47 customer projects, and the total number of side streams under evaluation is 58. The numbers speak for themselves - interest in NutraCycle is growing at a rapid pace.

The company has identified four film projects that have a good chance of reaching full financing during the year, which would make a clear contribution to both turnover and results already 2025.

Regarding exclusive rights and a commercial partnership to introduce BupiZenge™ in Europe.

The letter of intent takes Carbiotix one step closer to breakthrough and to go from being a promising company to becoming a growth company.

The Company is developing Ayla, the world's first dementia care platform for the scalable delivery of Cognitive Stimulation Therapy (CST), the leading non-pharmacological therapy for dementia.

Among other things, for eliminating bad odors and surface coatings. Impala Nordic sees several exciting value drivers ahead, including expected cash flow positivity after the end of Q1.

He also provides his perspective on the digital healthcare market and the key factors investors should keep an eye on in the coming years.

The subscription price amounts to 1.01 SEK, which could raise 6.5 MSEK, of which at least 5.8 MSEK is secured. CEO Peter Persson is subscribing for shares for almost 1 MSEK, and TO2 is expected to significantly strengthen the company's cash position.

Through the acquisition of Lion Gaming, the Company is fundamentally changing, with both a new focus and stronger finances. Lion Gaming's estimated turnover was SEK 51.7 million for 2024 with an EBITDA result of SEK 2.3 million.

Overall, the company continues in the right direction, and adjusted for changes in accounting procedures, growth appears strong.

In summary, 2025 will be an intense year for OncoZenge, where shareholders have several milestones to look forward to. Including the completion of the investment agreement with Yangtian and a finalized agreement with Molteni Farmaceutici.

The company reported a doubling of customer projects during Q4, where several collaborations are with companies with sales of over 10 billion USD.

In addition, he touches on the financial goals and the ambition to achieve a positive cash flow after Q1 2025

The company is currently conducting a rights issue where the capital will be used to commercialize LAMPlify® in the horse, pig and fish segments. The goal for 2025 is to deliver 40 platforms.

The capital will be used to start the phase 3 study of BupiZenge™ and to strengthen OncoZenge's position in the global market.

The agreement secures financial resources to carry out the Company's European Phase 3 study.

We view the news positively that Carbiotix once again demonstrates the ability to carry out an effective capital raising.

After the migration the number of charging points will increase from approximately 15,000 to 39,000.

They explain the reasons behind the decision not to communicate the launch date for the game title HELA, and provide insight into their financing strategy.

The goal is to sign a final license agreement by April 30, 2025.

He also shares his views on the biometrics market and what potential value drivers investors should keep an eye on in 2025.

The increase corresponds to a doubling, which means that the company now has a total of 32 ongoing customer projects and has surpassed Impala Nordic's base scenario in terms of customer projects.

The company develops and sells biometric cards, with a focus on the access management market.

The company is currently focusing on commercializing and out-licensing the up-cycling service NutraCycle.

OncoZenge will now work to explore partnerships with other stakeholders.

At the same time, the influx of new customers continues and the number of connected charging points is expected to reach 15,000 before the end of 2024.

Helene also answers how the capital from the upcoming rights issue will be used, and what growth ambitions the company has.

The news is considered a major breakthrough and proves that there is a clear path to market.

With patented and environmentally friendly technology, they aim to become cash flow positive in Q1 2025 and expand into markets such as Germany, North America and Asia.

He also mentions the company's plans to expand into other media, such as TV and film, and to grow its portfolio of intellectual property rights.

He also emphasizes the ongoing rights issue's importance for growth and transformation.

Glenn shares insights on ZignSec's growth strategy, client successes, and the recent public offering. Sergei explains how AI is transforming their products and meeting rising compliance demands in industries like cryptocurrency.

The company has recently broadened its operations to iGaming through the acquisition of Trustplay AB. The focus going forward is to grow within the iGaming sector and to work towards profitability. The upcoming rights issue will strengthen the Company's financial position and its potential for growth in the future.

He highlights Tangiamo's unique solutions, the integration of TrustPlay's products with existing offerings, key drivers for future growth, and the company's strategic goals for 2025.

Furthermore, Rambe elaborates on the significance of the acquisition for the venture in mobile media, as well as the significant revenue opportunities going forward.

We explore NutraCycle, the company's financial standing, competition, and team expansion.

Additionally, Mogensen discusses the medical need for patients suffering from oral mucositis and shares his hopes for the future of BupiZenge™.

Through the acquisition, Hoi becomes the majority owner of Eleven Stories AB, which is expected to increase Hoi's turnover will increase significantly in the coming years.

We note that this corresponds to a growth of approximately 57% compared to Q2, while being in line with our expectation of approximately SEK 7 million.

The company reduces the loss significantly compared to Q2 2023 and returns to growth during the quarter.

Her story underscores the urgent need for better pain relief solutions and highlights the often-overlooked challenges that patients face.

Impala Nordic produced the video on behalf of OncoZenge AB (publ).

Daniel outlines how ZignSec uses AI to automate compliance processes, ensuring both global scalability and adherence to regulatory requirements, while allowing experts to concentrate on high-risk cases. Daniel's approach ice to enhance efficiency and ensure security in digital identification.

She discusses the experiences from EQL Pharma and Respiratorius, as well as the company's CE-marked product LAMPlify® and plans for Panviral. The episode also discusses challenges and opportunities in the biotech and medtech sectors, Karin's view on the current stock market and financing climate for smaller companies, and strategies for securing capital.

During the visit, CEO Tomas Hammar and veterinarian Lisa Lidbeck talk about the importance of rapid diagnostics for competition horses. Karin Wehlin, CEO of Diagonal Bio, highlights the increasing demand for faster diagnostics in equestrian sports.

The group, which consists of several companies, jointly offers a wide range of RegTech solutions. The company is listed on First North Stockholm.

Ulf discusses the progress of the DIAGNODE-3 study, the significance of the FDA Fast Track designation, and the benefits of intralymphatic immunotherapy. He also provides an update on the production facility in Umeå, the company's financing situation, and concludes by answering listener questions.

The company sells and rents its instruments globally and is now conducting a share issue of 7.4 MSEK to strengthen marketing and participate in international congresses. PExA market includes both research instruments and future diagnostics, with the potential to revolutionize the detection and treatment of lung diseases.

The funds will also be used to hire seniors salespeople and conduct targeted campaigns.

The growth is mainly due to the acquisitions of Superlux Aps and Ekström & Garay AB. Impala Nordic expects continued increased sales during Q2 and Q3, with forecasts of SEK 7 million and SEK 8.5 million, respectively.

The company thus continues its growth journey and the forecast is to reach 15,000 connected charging points before the end of 2024.

He describes how the company generates revenue, the purpose of the new issue and strategies to stay competitive with new technology. He also highlights KYB solutions for payment processors and plans for future geographical expansion.

The episode discusses the current treatment options for oral mucositis and why BupiZenge represents a significant advance in the field. We also take a look at Chris' other roles as Chief Medical and Business Officer at Diamyd Medical AB (publ) and Melius Pharma.

By providing high-quality soluble fibers for the dietary supplement industry, Carbiotix aims to combat the global shortage of fiber. The company strengthens its position through the NutraCycle service that converts waste products into valuable fibers, promoting a healthier diet and sustainable production.

He also highlights the strategies that have contributed to the Company's impressive growth, including a turnover of 15.7 MSEK in 2023.

With an innovative instrument that enables the collection of samples from the lungs' small airways, Tomas shows how PExA opens up new opportunities for early detection and treatment of lung diseases. The company's customer base encompasses the global research community and ranges from studies related to the work environment to research on lung cancer.

Hoi Publishing is driving significant revenue growth and improved profitability. The company is listed on NGM.

This development underlines the potential for future product variants and confirms previous data. In parallel, the Company is exploring opportunities for partnerships in the Chinese market, with a focus on sales, clinical studies or licensing agreements.

The commitment from the investors was strong, which resulted in relevant questions and fruitful discussions.

Here we also learn about ZignSec's future goals and visions, including the ambition to reach 20 million euros in net sales by 2027 to create shareholder value.

The company's unique model, where the author and the publisher share the risk, creates good conditions for launching a large number of titles while limiting financial risk. Hoi ended 2023 with strong revenue growth and is completing a significant acquisition of the publisher Ekström & Garay and faces an exciting year ahead.

ZignSec's digital solutions allow companies to meet regulatory requirements for Know Your Customer (KYC) and Anti-Money Laundering (AML) in real time. With a projected market for digital ID verification solutions of over USD 30 billion by 2024, ZignSec faces significant growth opportunities.

The company has experienced impressive growth from 5 million SEK in 2021 to over 50 million SEK during 2023, with a positive operating profit reported for the fourth quarter of 2023. Adverty shows no signs of slowing down in growth, indicating a promising future for 2024.

The business model is centered on providing efficient solutions for remote onboarding and due diligence. The company's future prospects are emphasized through a strategy focused on geographical expansion and investments in AI and LLM technologies to meet evolving market needs and drive growth.

At the same time, discussions are underway with potential partners for a phase 3 study, where dialogue is being held with three different actors. In February, OncoZenge also submitted a new patent application, which, if approved, could give BupiZenge™ market exclusivity until 2045.

Hoi Publishing aims to expand its operations and reach a turnover of over 200 million SEK within five years, initially in the Nordics and then globally. For 2024, the focus is on strengthening the synergies from its acquisitions, increasing turnover and generating profit.

They highlight how they have overcome previous challenges and their focus on meeting patient needs ahead of Phase 3. They also share insights on partnership plans and product positioning, and emphasize the company's goal of increasing transparency and trust among investors and stakeholders.

Impala Nordic views the agreement positively, which is not only expected to generate revenue but also strengthen LAMPlify®'s market position.

Jonas sees good growth prospects for Adverty, especially considering the ability to triple revenue annually and show profit at the EBITDA and EBT level. In 2024, the company will focus on increasing its growth within both advertisers and game publishers, as well as on launching new products.

Their technology enables seamless ads and has driven strong growth and profit in Q4 2023. With success in the US and Europe and clients such as Red Bull and Coca Cola, Adverty's leadership in a game advertising industry expected to reach $131 billion by 2025 is strengthened.

The company also continues its global expansion with new customer agreements in Barbados and the Philippines and improves the connection process with the launch of the new service ConnectGO.

Peter also talks about the key parts of ChargePanel's growth strategy, their international expansion, and how they generate revenue. Finally, the current issue and the use of the capital are highlighted.

Currently, OncoZenge is working to secure PRIME status with the EMA, which can facilitate the regulatory process. With a drug candidate that has the potential to improve the quality of life for people with oral mucositis, OncoZenge faces exciting future opportunities.

During the interview, OncoZenge's strategies for getting the product to market, the collaboration with Ensysce Biosciences, the expansion to international markets, financial aspects and the goals for the company in 2024.

Management's goal is to achieve profitability and positive cash flow by the end of 2024 which is a trigger for the case.

The conversation covers various topics, including the company's growth strategy, customer flow, international presence and the increase in connected charging points in recent quarters. "We expect a 100% increase in the number of connected charging points year after year" - Peter Persson.

Who talks about the increasing ISK tax, why some savers try to time the market, the psychological factors behind investment decisions and concrete advice to avoid short-term decisions.

Witt highlighted plans for GT-002, aiming for development and commercialization post-Phase 2 studies, and concluded by outlining Gabather's main objectives for 2024. He also comments the ongoing rights issue where they raise SEK 28.6 million.

She highlights challenges, emphasizes the company's attractive business model and market position.

The company has also appointed Karin Wehlin as acting CEO after the board and the former CEO, Jack Egelund Madsen, jointly decided that Jack should resign.

A wonderful commitment and many wise questions were discussed.

We look forward to a continued fruitful partnership and exciting projects in the future in collaboration with Goobit Group.

They've recently opted for a directed share issue and loan to strengthen the impact and focusing on the commercialization of LAMPlify™, recently CE-marked. Diagonal Bio aims to generate revenue and continue its innovative journey.

The company has a strong pipeline ahead of it and aims to obtain CE marking for LAMPlify and then launch and commercialize its LAMPlify system for biomarker identification in 2023.

Ina also shares what the company has for plans ahead.

In this interview you will get to know the company Scandinavian Real Heart and the company's CEO, Ina Laura Perkins. You will also hear more about the pre-clinical studies, the current new share issue and Real Heart's future plans and visions.

We also gain insight into how Feminvest supports female entrepreneurs and investors.

Jack too answers questions about Diagonal's two technologies - LAMPlify™ and PANVIRAL™.

The company has shown an impressive annual revenue growth of 25% over the past three years and, supported by structural trends such as deregulation and digitalization, the company is facing an exciting growth journey.

The platform creates conditions for innovation and growth for both listed companies and investors.

She questions why this day is still needed to remind us that women and men are equally valuable.

Erik shares the company's annual growth targets to be achieved through expansion, increased profitability and a continued clear pipeline for more acquisitions.

"Despite his young age, we have seen a strong ability in how Vilhelm analyzes companies and I am convinced that he will do a fantastic job at us" - Ylber Rexhepi.

MeeW conducts a new share issue in connection with an IPO and Armin thereby tells us how the issue proceeds will be used to internationalize MeeW.

He also talks about future investment opportunities within Medtech and what to consider before such investments.

Jenny has many years of experience in the financial industry and in leadership and works actively to convey the importance of companies measuring EQ among their management and its employees.

"A few days have passed and we can already see what a top candidate Isabella is, she is super creative and has quickly added value to us" - Aya Salar.

He explains the pros and cons of investing in under-analyzed companies and why they focus on Nordic small companies.

All competition terms and conditions can be read on our Instagram account